Neratinib News and Research

RSS

Unraveling the role of HER2 mutant alleles in breast cancer

A new editorial paper was published in Oncotarget's Volume 14 on October 31, 2023, entitled, "The uncharted role of HER2 mutant alleles in breast cancer."

6 Nov 2023

Adaptive platform trial shows promise for finding new glioblastoma therapies

An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.

19 Sep 2023

Study finds a more effective treatment option for HER2 mutant metastatic breast cancer

Breast cancers with HER2 mutations respond to the drug neratinib, but the responses are variable and often not durable.

23 Jun 2022

Potential covalent SARS-CoV-2 spike protein inhibitors

There remains a significant need for new and effective drugs that can be used to treat COVID-19.

23 Sep 2021

Simple blood tests can benefit women with breast cancer

A blood test that can identify a variety of mutations in advanced breast cancer can reliably match women to effective targeted treatments, early results of a major clinical trial reveal.

11 Sep 2020

Existing drug used to treat alcoholism is potentially effective against COVID-19

A team of chemists from HSE University and the Zelinsky Institute of Organic Chemistry used molecular modelling to find out that two medications that have been known for a long time can be used to fight SARS-CoV-2.

5 Aug 2020

A two-drug combo that halts growth of cancer cells discovered

UT Southwestern Simmons Cancer Center researchers have discovered a two-drug combo that halts the growth of cancer cells that carry HER2 mutations.

23 Jan 2020

Yale scientists build powerful genomic research platform to study cervical cancer

Yale Cancer Center scientists have built a powerful genomic research platform to study cervical cancer, a disease that often is untreatable if it progresses after surgery or primary chemo-radiation treatment.

17 Oct 2019

Drug that treat human breast cancer might also work for canine lung cancer

Despite those velvet paintings of poker-playing dogs smoking pipes, cigars and cigarettes, our canine friends really don't use tobacco. But like many humans who have never smoked, dogs still get lung cancer.

21 Aug 2019

Two genomic tests help identify most effective treatment for breast cancer patients

New results from a long-running trial to identify which new drugs or combinations of drugs are most effective in which types of breast cancer, show that two genomic tests are bringing the era of truly personalized medicine ever nearer.

14 Nov 2018

Experts propose new solutions to increase benefit, affordability of targeted cancer medicines

Spending on cancer drugs in the United States has nearly doubled in the past five years and continues to grow, imposing substantial financial burden on patients with cancer.

18 Apr 2018

Tumor's 'microenvironment' plays key role in altering therapeutic response of breast cancer

Cancer is typically thought of as a tumor that needs to be removed or an area that needs to be treated with radiation or chemotherapy. As a physicist and cancer researcher, Joe Gray, Ph.D., thinks differently.

14 Mar 2018

FDA approves first extended adjuvant therapy to lower risk of breast cancer recurrence

The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer.

18 Jul 2017

I-SPY2 research initiative employs exciting new model for testing breast cancer drugs

In a new paradigm of breast cancer research, physicians are fast-tracking promising new experimental drugs for further study, while immediately dropping drugs and drug combinations that don't work.

8 Jul 2016

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Scientists discover important new biomarker that could improve HER2 targeted cancer treatments

Scientists from the School of Pharmacy & Pharmaceutical Sciences, Trinity College Dublin have made a significant discovery of a new biomarker which may help overcome resistance to newer and more targeted anti-cancer drugs, such as Herceptin, for HER2 positive cancers. These findings may also help the early identification of patients who will benefit more from these treatments.

11 Jun 2014

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer.

8 Apr 2014

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).

11 Mar 2014

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

The I-SPY 2 TRIAL, a randomized phase II clinical trial for breast cancer launched through a unique partnership with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and sponsored by QuantumLeap Healthcare Collaborative has graduated the first two drugs from its innovative, multidrug standing platform trial.

27 Dec 2013

Researchers test promising new breast cancer drugs

The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.

14 Dec 2013